SCHEMBL5014536

SCHEMBL5014536

COc1cccc(C2=NOC3(CCN(C(=O)C4c5ccccc5-c5ccccc54)CC3)C2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.51
ALDH1A1 P00352 3/20 0.51
RAB9A P51151 2/20 0.51
HTT P42858 2/20 0.51
NPY5R Q15761 1/20 0.45
TSHR P16473 2/20 0.44
TP53 P04637 1/20 0.44
TDP1 Q9NUW8 2/20 0.40
MAPT P10636 2/20 0.40
CYP1A2 P05177 2/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2C19 P33261 2/20 0.40
RECQL P46063 2/20 0.40
POLB P06746 1/20 0.40
APEX1 P27695 1/20 0.40
USP2 O75604 1/20 0.40
HPGD P15428 1/20 0.40
ALOX15 P16050 1/20 0.40
CASP1 P29466 1/20 0.40
CYP2C9 P11712 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5015686 0.91 ALDH1A1 (0.49) NPC1ALDH1A1RAB9AHTTNPY5R
SCHEMBL5120699 0.84 HTT (0.38) NPC1ALDH1A1RAB9AHTTNPY5R
SCHEMBL15855842 0.83 NPC1 (0.51) NPC1ALDH1A1RAB9AHTTNPY5R
SCHEMBL5015805 0.79 NPC1 (0.46) NPC1ALDH1A1RAB9AHTTNPY5R
SCHEMBL5121286 0.79 SMN1; SMN2 (0.55) NPC1ALDH1A1RAB9AHTTNPY5R
SCHEMBL5012919 0.79 NPC1 (0.46) NPC1ALDH1A1RAB9AHTTTSHR
SCHEMBL5131274 0.79 NPY5R (0.50) NPC1ALDH1A1RAB9AHTTNPY5R
SCHEMBL5015782 0.78 NPC1 (0.45) NPC1ALDH1A1RAB9AHTTNPY5R
SCHEMBL5124433 0.78 SMN1; SMN2 (0.61) NPC1ALDH1A1RAB9AHTTNPY5R
SCHEMBL5129518 0.77 TSHR (0.53) ALDH1A1HTTTSHRTP53TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8772307-B2 Substituted spiro compounds and their use for producing pain-relief medicaments GRUENENTHAL GMBH (DE) 2014-07-08 US claimed
US-20080269271-A1 Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders GRUENENTHAL GMBH (DE) 2008-10-30 US claimed
EP-1888596-A1 SUBSTITUTED SPIRO COMPOUNDS AND THEIR USE FOR PRODUCING PAIN-RELIEF MEDICAMENTS Grünenthal GmbH (DE) 2008-02-20 EP claimed
WO-2006122770-A1 SUBSTITUTED SPIRO COMPOUNDS AND THEIR USE FOR PRODUCING PAIN-RELIEF MEDICAMENTS Grünenthal GmbH (DE) 2006-11-23 WO claimed
EP-1888596-B1 SUBSTITUTED SPIRO COMPOUNDS AND THEIR USE FOR PRODUCING PAIN-RELIEF MEDICAMENTS GRUENENTHAL GMBH (DE) 2014-10-22 EP disclosed
US-20080269271-A1 Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders GRUENENTHAL GMBH (DE) 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269271-A1 Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders INA, SCN1A, SI NPC1 785/4885ALDH1A1 511/4885RAB9A 2540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.